Associated Papers
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
Cheng WY et al.
Blood, 2025
40829168 (PubMed )
Supplement: BLOOD_BLD-2024-027692-mmc5.xlsx › Sheet_1
CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases.
González-Guerrero L et al.
Diagnostic Pathology, 2025
40307896 (PubMed )
Supplement: 13000_2025_1655_MOESM1_ESM.docx
Aging and comprehensive molecular profiling in acute myeloid leukemia.
Li JF et al.
Proceedings of the National Academy of Sciences of the United States of America, 2024
38422020 (PubMed )
Supplement: pnas.2319366121.sd02.xlsx › Sheet_1
Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.
Cheng WY et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
36442087 (PubMed )
Supplement: pnas.2211429119.sd02.xlsx › snv_indel
Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
Sarojam S et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2015
Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2010
Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.
Pabst T et al.
British Journal of Cancer, 2009
19277035 (PubMed )
Supplement: 6604977x1.doc
Select a paper to view details